Yervoy hits the market with $95M bang

Market watchers expected Bristol-Myers Squibb's ($BMY) new cancer drug to be big, but this fast? The company's second-quarter sales left Wall Street estimates in the dust and prompted an increase in profit forecasts, largely thanks to unexpectedly strong sales of the very-recently-approved Yervoy.

Indeed, the melanoma treatment just won the FDA nod in March, and it has already brought in $95 million, Reuters reports. "To come up with nearly $100 million in sales right out of the gate is fantastic," Credit Agricole Securities analyst David Maris, who had projected Yervoy sales of $20 million, told the news service. Peak sales are forecast to hit at as much as $6 billion.

Companywide sales came in at $5.43 billion, well over expectations of $5.04 billion. Nine of its 10 top drugs beat analyst estimates for the quarter, Bloomberg notes. Strong performers included the antipsychotic Abilify, which saw sales rise by 12% to $706 million, and leukemia treatment Sprycel, which boosted sales by 46% to $193 million. Earnings per share were at 56 cents, a penny better than the 55 cents analysts had predicted, but the company raised its forecast by a full 10 cents.

Chuffed by the numbers, and by the potential approval of Bristol's new clot-prevention drug apixaban, Sanford Bernstein analyst Tim Anderson told clients, "Bristol-Myers remains hands down the best pipeline story among the U.S. and European pharmaceutical companies we cover. 2011 is likely to be a buy year."

- get the news from Reuters
- see the Bloomberg story

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.